ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET FORECAST 2019-2028

  • You are here:
  • Home
  • Reports
  • ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET FORECAST 2019-2028

ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET FORECAST 2019-2028

The Asia Pacific antihypertensive drugs market is estimated to garner a CAGR of 4.32%, during the forecast years of 2019 to 2028. The region provides lucrative opportunities for the market, and is therefore projected to register the highest growth rate through the forecast period. The Asia Pacific antihypertensive drugs market growth analysis is conducted across countries including, India, South Korea, Indonesia, Australia & New Zealand, China, Japan, Thailand, Vietnam, and the rest of Asia Pacific.

ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET FORECAST 2019-2028

Asia Pacific Antihypertensive Drugs Market by Drug Class (Calcium Channel Blockers, Ace Inhibitors, Beta-adrenergic Blockers, Diuretics, Vasodilators, Other Drug Class) by End-user (Hospital Pharmacy, Retail Pharmacy, E-commerce Websites & Online Drug Stores) and by Geography.

Request free sample

The Asia Pacific antihypertensive drugs market is estimated to garner a CAGR of 4.32%, during the forecast years of 2019 to 2028. The region provides lucrative opportunities for the market, and is therefore projected to register the highest growth rate through the forecast period.
Asia Pacific Antihypertensive Drugs Market

To know more about this report, request a free sample copy.

The Asia Pacific antihypertensive drugs market growth analysis is conducted across countries including, India, South Korea, Indonesia, Australia & New Zealand, China, Japan, Thailand, Vietnam, and the rest of Asia Pacific. Key factors that fuel the antihypertensive drugs market growth in China comprise the increase in government schemes and initiatives for improving the healthcare sector, combined with the predominance of Chronic Obstructive Pulmonary Disease (COPD). According to the American Association for the Advancement of Science (AAAS), COPD is among the dominant causes of death. The chronic disease may also cause pulmonary hypertension, which is marked by high blood pressure in the arteries that carry blood to the lungs. Moreover, increased pollution levels have also factored in, to drive the market growth. The rising population exposed to air pollution is a leading cause of respiratory diseases, which, in turn, is predicted to propel the market growth in the region.

The Ministry of Health and Welfare declared that the prevalence of chronic diseases like hyperlipidemia, diabetes, and hypertension in South Korea is consistently rising. Therefore, a surge in such conditions incorporated with mounting respiratory problems in the country is expected to fuel the market growth.

Headquartered in Mumbai, India, Lupin Limited is the third-largest pharmaceutical company in India, based on global revenue and the fourth largest pharmaceutical enterprise in the United States, based on prescription volume. The company has marked its significance in the fields of cardiovascular, diabetology, asthma, central nervous system, and pediatrics, among others. Lupin Limited also holds a global leadership position in the anti-TB segment.

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

  1. RESEARCH SCOPE & METHODOLOGY
    • STUDY OBJECTIVES
    • SCOPE OF STUDY
    • METHODOLOGY
    • ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    • MARKET SIZE & ESTIMATES
    • MARKET OVERVIEW
  3. MARKET DYNAMICS
    • MARKET DEFINITION
    •    KEY DRIVERS
      • GROWING PREVALENCE OF HYPERTENSION ACROSS THE GLOBE
      • SURGE IN DISPOSABLE INCOME AND HEALTHCARE SPENDING
      • RISING AGING POPULATION
    •    KEY RESTRAINTS
      • PATENT EXPIRATIONS
      • DELAY IN PRODUCT LAUNCHES
  1. KEY ANALYTICS
    •    PORTER’S FIVE FORCE ANALYSIS
      • THREAT OF NEW ENTRY
      • THREAT OF SUBSTITUTION
      • BUYER’S POWER
      • SUPPLIER’S POWER
      • COMPETITIVE RIVALRY
    • REGULATORY FRAMEWORK
    • OPPORTUNITY MATRIX
    • VENDOR LANDSCAPE
    • KEY INVESTMENT INSIGHTS
  2. MARKET BY DRUG CLASS
    • CALCIUM CHANNEL BLOCKERS
    • ACE INHIBITORS
    • BETA-ADRENERGIC BLOCKERS
    • DIURETICS
    • VASODILATORS
    • OTHER DRUG CLASS
  3. MARKET BY END-USER
    • HOSPITAL PHARMACY
    • RETAIL PHARMACY
    • E-COMMERCE WEBSITES & ONLINE DRUG STORES
  4. GEOGRAPHICAL ANALYSIS
    •    ASIA PACIFIC
      • CHINA
      • JAPAN
      • INDIA
      • AUSTRALIA & NEW ZEALAND
      • SOUTH KOREA
      • THAILAND
      • INDONESIA
      • VIETNAM
      • REST OF ASIA PACIFIC
  1. COMPANY PROFILES
    • ALLERGAN PLC
    • ASPIRE BARIATRICS INC
    • ASTRAZENECA PLC
    • BIO-RAD LABORATORIES INC
    • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • DAIICHI SANKYO COMPANY LIMITED
    • HILL-ROM HOLDINGS INC
    • JOHNSON & JOHNSON
    • LUPIN LIMITED
    • MEDTRONIC PLC
    • MERCK & CO INC
    • NOVARTIS AG
    • PFIZER INC
    • SANOFI
    • SUN PHARMACEUTICAL INDUSTRIES LTD (RANBAXY LABORATORIES)

TABLE LIST

TABLE 1: MARKET SNAPSHOT – ANTIHYPERTENSIVE DRUGS

TABLE 2: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY DRUG CLASS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 3: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY DRUG CLASS, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 4: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 5: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY END-USER, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 6: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 7: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)

FIGURES LIST 

FIGURE 1: PORTER’S FIVE FORCE ANALYSIS

FIGURE 2: OPPORTUNITY MATRIX

FIGURE 3: VENDOR LANDSCAPE

FIGURE 4: KEY INVESTMENT INSIGHTS

FIGURE 5: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY DRUG CLASS, IN 2019

FIGURE 6: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY CALCIUM CHANNEL BLOCKERS, 2019-2028 (IN $ MILLION)

FIGURE 7: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY ACE INHIBITORS, 2019-2028 (IN $ MILLION)

FIGURE 8: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY BETA-ADRENERGIC BLOCKERS, 2019-2028 (IN $ MILLION)

FIGURE 9: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY DIURETICS, 2019-2028 (IN $ MILLION)

FIGURE 10: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY VASODILATORS, 2019-2028 (IN $ MILLION)

FIGURE 11: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY OTHER DRUG CLASS, 2019-2028 (IN $ MILLION)

FIGURE 12: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY END-USER, IN 2019

FIGURE 13: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY HOSPITAL PHARMACY, 2019-2028 (IN $ MILLION)

FIGURE 14: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY RETAIL PHARMACY, 2019-2028 (IN $ MILLION)

FIGURE 15: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY E-COMMERCE WEBSITES & ONLINE DRUG STORES, 2019-2028 (IN $ MILLION)

FIGURE 16: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)

FIGURE 17: CHINA ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 18: JAPAN ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 19: INDIA ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 20: AUSTRALIA & NEW ZEALAND ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 21: SOUTH KOREA ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 22: THAILAND ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 23: INDONESIA ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 24: VIETNAM ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 25: REST OF ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)

  1. GEOGRAPHICAL ANALYSIS
    •    ASIA PACIFIC
      • CHINA
      • JAPAN
      • INDIA
      • AUSTRALIA & NEW ZEALAND
      • SOUTH KOREA
      • THAILAND
      • INDONESIA
      • VIETNAM
      • REST OF ASIA PACIFIC
  1. MARKET BY DRUG CLASS
    • CALCIUM CHANNEL BLOCKERS
    • ACE INHIBITORS
    • BETA-ADRENERGIC BLOCKERS
    • DIURETICS
    • VASODILATORS
    • OTHER DRUG CLASS
  2. MARKET BY END-USER
    • HOSPITAL PHARMACY
    • RETAIL PHARMACY
    • E-COMMERCE WEBSITES & ONLINE DRUG STORES

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now